RxDoctor Payments Data

Paul Sutera, MD

Pain Medicine · Mohave Valley, AZNPI 1740270750

Payments from drug & device makers

$2,177in general payments, 2019–2025

Across 113 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$921
  • Medtronic$670
  • Biodelivery Sciences International, Inc.$116
  • Nevro Corp.$85
  • Daiichi Sankyo Inc.$66
  • Pfizer$59
  • plus $260 from 11 others

What the payments were for

  • Food & beverage$2,15899%
  • Entertainment$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,177 in reported general payments places this provider in the 30th percentile of 180 pain medicine providers in Arizona.

See all pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$97,726
Medicare patients
179
Services billed
1,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate36$23,867
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen801$17,795
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen633$15,259
Oxycodone Hcl750$13,835
Fentanyl94$10,794
Morphine Sulfate ErMorphine Sulfate342$6,075
Gabapentin430$5,457
OxycontinOxycodone Hcl13$3,899
Morphine Sulfate138$3,454
Buprenorphine13$3,255
Lidocaine38$3,166
Pregabalin120$2,499
Hydromorphone Hcl60$2,298
Acetaminophen-CodeineAcetaminophen With Codeine53$1,499
Tramadol Hcl167$1,298

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$16$23,86736 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 180 pain medicine providers in Arizona.

Other pain medicine in Mohave Valley

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →